Links between Pharmaceutical R&D Models and Access to Affordable Medicines
Each patient in the European Union has a right of access to care. National governments face the challenge to balance resources against healthcare demand to ensure that populations enjoy equitable access to effective, affordable and sustainable healthcare. This study describes the main challenges with regard to access to affordable medicines, including Research & Development, pricing and reimbursement of medicines and the influence of the economic crisis. Potential policy options to tackle these challenges are presented, drawing on best practices and a review of specific measures implemented in different European countries. This document was provided by Policy Department A for the Committee on the Environment, Public Health and Food Safety.
Studie
Extern avdelning
Brian GODMAN, Wija OORTWIJN, Chiara DE WAURE, Ilaria MOSCA, Anna PUGGINA, Maria Lucia SPECCHIA, Paolo CAMPANELLA and Jeroen VAN DER TUIN
Om detta dokument
Publikationstyp
Politikområde
Sökord
- demografi och befolkning
- EKONOMI
- ekonomisk analys
- EU-statistik
- europeisk integration
- EUROPEISKA UNIONEN
- FINANSER
- forskning och immateriell äganderätt
- forskning och utveckling
- försörjning
- HANDEL OCH AFFÄRSVERKSAMHET
- handelsutbyte
- hälsa
- hälso- och sjukvårdskostnader
- inre marknad
- konsumentpris
- läkemedelskostnader
- läkemedelslagstiftning
- läkemedelsprissättning
- medicin
- pris
- PRODUKTION, TEKNIK OCH FORSKNING
- SOCIALA FRÅGOR
- åldrande befolkning